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Emerging evidence indicates that disruption of the gut microbial community (dysbiosis) impairs mental
health. Germ-free mice and antibiotic-induced gut dysbiosis are two approaches to establish causality in
gut microbiota-brain relationships. However, both models have limitations, as germ-free mice display
alterations in blood-brain barrier and brain ultrastructure and antibiotics may act directly on the brain.
We hypothesized that the concerns related to antibiotic-induced gut dysbiosis can only adequately be
addressed if the effect of intragastric treatment of adult mice with multiple antibiotics on (i) gut micro-
bial community, (ii) metabolite profile in the colon, (iii) circulating metabolites, (iv) expression of neu-
ronal signaling molecules in distinct brain areas and (v) cognitive behavior is systematically
investigated. Of the antibiotics used (ampicillin, bacitracin, meropenem, neomycin, vancomycin), ampi-
cillin had some oral bioavailability but did not enter the brain. 16S rDNA sequencing confirmed
antibiotic-induced microbial community disruption, and metabolomics revealed that gut dysbiosis was
associated with depletion of bacteria-derived metabolites in the colon and alterations of lipid species
and converted microbe-derived molecules in the plasma. Importantly, novel object recognition, but not
spatial, memory was impaired in antibiotic-treated mice. This cognitive deficit was associated with brain
region-specific changes in the expression of cognition-relevant signaling molecules, notably brain-
derived neurotrophic factor, N-methyl-D-aspartate receptor subunit 2B, serotonin transporter and neu-
ropeptide Y system. We conclude that circulating metabolites and the cerebral neuropeptide Y system
play an important role in the cognitive impairment and dysregulation of cerebral signaling molecules
due to antibiotic-induced gut dysbiosis.
 2016 The Authors. Published by Elsevier Inc. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
The digestive tract is colonized by trillions of microbes, collec-
tively termed gut microbiota. This extensive microbial community,
comprising approximately 1012 colony-forming units/mL in the
colon, influences gastrointestinal physiology as well as function
of distant organs and susceptibility of the host to disease
(Lozupone et al., 2012). Detailed analysis indicates that the gut
microbiota regulates the development and function of the brain,
and that disturbances of the microbial community may contribute
to neuropsychiatric diseases (Collins et al., 2012; Cryan and Dinan,
2012; Bienenstock et al., 2015; De Palma et al., 2015; Sampson and
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on the brain may involve metabolic, immune, endocrine and neu-
ronal pathways (Cryan and Dinan, 2012; Sharon et al., 2014; Liu
et al., 2015), but gut microbiota-brain communication is still
insufficiently understood.
Studies in germ-free (GF) mice have been crucial in establishing
a causal role of the commensal gut microbiota in shaping brain
function and behavior (Stilling et al., 2014a). GF mice, raised under
sterile conditions, have been shown to display changes in anxiety-
like, social and cognitive behavior (Gareau et al., 2011; Diaz Heijtz
et al., 2011; Desbonnet et al., 2014; Stilling et al., 2014b). However,
they represent a highly artificial model that is characterized by a
leaky blood-brain barrier (Braniste et al., 2014) and alterations in
brain structure and neurochemistry (Diaz Heijtz et al., 2011). In
addition, compensatory processes are likely to dampen physiologic
deficits caused by the life-long absence of microbiota. In view of
these considerations, antibiotic-induced short-term disruption of
the intestinal microbial community (dysbiosis) is thought to be a
less intrusive model to probe causality in microbiota-dependent
effects (Bercik et al., 2011; Farzi et al., 2012; Desbonnet et al.,
2015). Possible drawbacks of antibiotic-induced gut dysbiosis are
systemic or even central effects of the antibiotics themselves and
alterations in ingestion if the antibiotics are administered via the
drinking water.
Given that short-term antibiotic treatment impairs cognitive
performance (Farzi et al., 2012), we hypothesized that this effect
is due to gut dysbiosis, alterations in gut microbiota-brain commu-
nication via microbial metabolites, and/or dysregulation of neu-
ronal signaling systems in the brain. To this end, we examined
the effects of intragastric treatment of adult mice with multiple
antibiotics on gut microbial community, metabolite profile in colon
and circulation, expression of select neuronal signaling molecules
in distinct brain areas, and cognitive behavior. With this systematic
investigation and a pharmacokinetic analysis of the antibiotics
under study we consider antibiotic-induced gut dysbiosis a valid
approach to establish causality in gut microbiota-brain relation-
ships, relative to GF mice. In addition, we suppose that circulating
metabolites and distinct signaling systems in the brain, such as the
neuropeptide (NPY) system, make an important contribution to gut
dysbiosis-associated brain dysfunction.2. Materials and methods
2.1. Experimental animals
The experiments were carried out with adult male C57BL/6N
mice obtained from Charles River Laboratories (Sulzfeld,
Germany). Mice were kept in groups of two to three. Light conditions
(12 h light/dark cycle), temperature (set point 22 C) and relative air
humidity (set point 50%) were tightly controlled. Throughout the
experiments tap water and standard laboratory chow were
provided ad libitum.2.2. Ethics statement
The experimental procedures and number of animals used were
approved by the ethical committee at the Federal Ministry of
Science, Research and Economy of the Republic of Austria (BMW
F-66.010/0026-WF/II/3b/2014) and conducted according to the
Directive of the European Parliament and of the Council of Septem-
ber 22, 2010 (2010/63/EU). The experiments were designed in such
a way that both the number of animals used and their suffering
was minimized.2.3. Experimental groups and timelines
To minimize environmental stress, mice were transferred to the
behavioral test room (12 h light/dark cycle, set points 22 C and
50% relative air humidity, maximal light intensity 100 lux) 2 days
before the start of the antibiotic treatment and maintained in this
room until sacrifice.
Animals were allocated to one of three groups (Fig. 1). Group A
was subjected to a behavioral test battery consisting of the open
field test on days 7, 8 and 9, elevated plus maze test on day 8, tail
suspension test on day 9, and novel object recognition test (NORT)
on day 10. Group B was habituated to the Barnes maze (BM) on day
7. BM training sessions were performed on days 8 and 9, and the
probe session was conducted on day 10. Groups A and B were sac-
rificed on day 11. Plasma, colon, luminal colonic contents, and
brain tissues collected from group A were used for molecular anal-
ysis. Group C was also treated with vehicle or the antibiotic mix
but was not subjected to any behavioral tests; they were sacrificed
on day 10 (the time point of cognitive testing) for analysis of
antibiotic concentrations in blood and brain and for histological
examination of the colon (Fig. 1). In all experiments, vehicle- and
antibiotic-treated animals were run in parallel.
2.4. Antibiotic mix
An antibiotic mix consisting of ampicillin (ampicillin sodium
salt, catalogue number A9518, Sigma-Aldrich, Vienna, Austria),
bacitracin (bacitracin from Bacillus licheniformis, catalogue number
11702, Sigma-Aldrich), meropenem (OptinemR, AstraZeneca
Österreich GmbH, Vienna, Austria), neomycin (neomycin trisulfate
salt hydrate, catalogue number N5285, Sigma-Aldrich) and van-
comycin (vancomycin hydrochloride from Streptomyces orientalis,
catalogue number 4747, Sigma-Aldrich) was used to deplete the
gut microbiota.
2.5. Antibiotic treatment
At the age of 8–11 weeks mice were treated with a mix of five
antibiotics (pH 6.98–7.14) or vehicle (distilled water) by oral gav-
age (10 mL/kg) for 11 days (Fig. 1). The antibiotics (108.0 mg baci-
tracin, 108.0 mg neomycin, 43.2 mg ampicillin, 21.6 mg
meropenem, 6.48 mg vancomycin) were dissolved in 4.5 mL dis-
tilled water. Dosing of antibiotics was based on studies where
ampicillin (Membrez et al., 2008; Khosravi et al., 2014;
Desbonnet et al., 2015), bacitracin and neomycin (Bercik et al.,
2011), meropenem (Moller et al., 2005; Gadjeva et al., 2010) and
vancomycin (Lawley et al., 2012) were added to the drinking water.
The antibiotic concentrations used in these studies were converted
to equivalent gavage doses, calculated relative to the average daily
water intake. Each day the mice were weighed before the first gav-
age, and the gavage volume was adjusted accordingly. Because of
their coprophagic behavior all cage mates received the same treat-
ment. For each gavage session 4.5 mL of the antibiotic mix was pre-
pared and used within 18 h. From the first day of treatment (day 0)
until day 6 the mice were gavaged twice daily (8:00 am, 5:00 pm).
On day 7 the mice were gavaged shortly after the open field test
(12:00 am) and before onset of the dark phase (5:00 pm). From
day 8 onwards the mice were gavaged once daily at 3:00 pm (after
the behavioral testing of the mice scheduled for the respective day
had been completed). The mice received the last treatment at
3:00 pm on the day before sacrifice (day 11).
2.6. Novel object recognition test
Mice were habituated to the open field box (as described in the
open field test in the Supplementary Data) each day during three
Fig. 1. Experimental groups and time lines. Mice of group A were subjected to a test battery including OFT, EPM test, TST and NORT. After sacrifice, tissues of group A animals
were analyzed as indicated. Mice of group B were habituated and trained in the BM. Animals of group C were not subjected to any behavioral tests but euthanized on day 10
(the day of cognitive evaluation in group A and B) to measure antibiotic concentrations in plasma and brain and investigate the effect of antibiotics alone on colon histology.
In all experiments vehicle (VEH)- and antibiotic (AB)-treated animals were run in parallel, the number of mice in each group being indicated in brackets. OFT, open field test;
EPM, elevated plus maze; TST, tail suspension test; NORT, novel object recognition test; BM, Barnes maze; qPCR, quantitative real-time polymerase chain reaction.
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the open field apparatus and given 5 min to explore two objects
that were placed at adjacent edges of the central area of the field.
One hour later the animals were re-exposed to one familiar object
(old object) together with a novel object (new object) for 5 min.
The exploratory behavior directed at each object was recorded in
both sessions. The time of object exploration was measured with
the VideoMot2 software (TSE Systems, Bad Homburg, Germany)
and the performance of each mouse was expressed by the memory
index (MI) according to the formula: MI = (tn  to)/(tn + to). The
time exploring the new object is represented by tn, whereas to rep-
resents the time exploring the old object (Redrobe et al., 2004).
Mice that explored the objects for less than 5 s in total were
excluded from the results. To avoid spatial and object bias, the
position of objects was alternated between trials, and the choice
of familiar versus novel object was changed from mouse to mouse.
After each test session the objects were cleaned with 70% ethanol.2.7. Barnes maze
The BM test protocol was adapted from that used by Attar et al.
(Attar et al., 2013), with minor modifications. In short, the BM
apparatus consisted of a circular white polyvinyl chloride slab with
a diameter of 91 cm elevated 61.5 cm above the floor. At a distance
of 2.5 cm from the edge, 20 holes with a diameter of 5 cm were
evenly distributed along the perimeter. Below the surface of the
maze a small escape cage was affixed underneath one of the 20
holes (target hole). The surface of the BM was illuminated by
35 lux. Four visual cues (colored circles and squares) were
mounted around the room for spatial orientation on the slab. The
animals were subjected to the BM test on three consecutive days.
On day 7 the mice were habituated to the BM, and on days 8 and
9 the mice were trained to quickly find and enter the escape hole.
This short training phase consisted of two training trials on day 8
and three training trials on day 9. The probe session during which
no escape cage was affixed to the BM apparatus was scheduled on
day 10. The movements of the mice on the training and probe dayswere tracked for 2 min with a video camera and evaluated with the
VideoMot2 software. Spatial learning manifested itself in a short-
ening of the latency to identify the target hole (target latency) dur-
ing consecutive training trials. Spatial memory was assessed by the
time the mice spent in the target area (quadrant of BM with target
hole in the center) on the probe day. To avoid spatial or visual cue
bias, the location of the escape cage was alternated after every
three mice. After each test session the BM and escape cage were
cleaned with 70% ethanol. Mice which did not learn the correct
position of the target hole, or did not voluntarily enter the escape
cage, were excluded from the evaluation.
2.8. Blood and tissue harvesting for biochemical analysis
Animals were anesthetized with pentobarbital (150 mg/kg i.p.).
Blood was drawn via cardiac puncture with a syringe that was
filled with 100 lL of 3.8% sodium citrate as anticoagulant. The
average blood vs sodium citrate ratio was 4:1. After 15 min of cen-
trifugation at 4 C and 7000 rpm, blood plasma was collected and
stored at 70 C. Following blood collection, brains were collected
and immediately frozen in 2-methylbutane (Sigma-Aldrich) on dry
ice for 5 s. Afterwards the brains were wrapped in aluminum foil
and kept at 70 C. For microbiome and metabolome analyses
the large intestine including the luminal contents was removed
and stored at 70 C.
2.9. Microbiome analysis
Frozen colon tissue including the luminal contents was homog-
enized on a MagNA Lyser Instrument using MagNA Lyser Green
Beads (Roche Diagnostics GmbH, Mannheim, Germany). Bacterial
DNA was extracted with the Power Lyzer Power Soil DNA Isola-
tion Kit (Mo Bio Laboratories, Inc., Carlsbad, CA, USA) according to
the manufacturer’s instructions. Subsequently, the DNA concentra-
tion was determined, and bacterial 16S rRNA was amplified by PCR
with the Rotor-Gene SYBR Green PCR Kit (Qiagen, Hilden,
Germany) using 20 ng DNA as template. To this end, the 16S primers
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were used as fusion primers containing Ion Torrent sequencing
adapters. In order to assess contaminations imported during the
microbiome analysis workflow, a sample devoid of any tissue and
colon content (blank) was included in the PCR run. Afterwards PCR
products were gel-purified and the amplicon DNA concentration
was determined. Sequencing of pooled amplicons was performed
with the Ion PGM Sequencer and an Ion Sequencing 400 Kit (both
from Life Technologies, Carlsbad, CA, USA). Contaminating non-
bacterial sequences were removed and Acacia error correction was
applied on all reads using standard parameters (Bragg et al., 2012).
Chimeras were identified by Usearch algorithm and removed. The
resulting bam file was introduced into QIIME (v1.8.0) 16S workflow
(www.qiime.org) (Caporaso et al., 2010). Differences in microbial
communities between groups were investigated using the
phylogeny-based weighted UniFrac distance metric. Alpha diversity
and ADONIS calculations were performed with the respective QIIME
scripts (alpha_diversity.py and compare_categories.py).
2.10. Brain microdissection
The working area and dissection instruments were cleaned with
RNeasy AWAY (Carl Roth, Karlsruhe, Germany). The microdissec-
tion was performed by a trained researcher on a cold plate
(Weinkauf Medizintechnik, Forchheim, Germany) set at 20 C as
described previously (Brunner et al., 2014). The dissected brain
tissues (medial prefrontal cortex, hypothalamus, amygdala,
hippocampus) were collected in micro packaging vials filled with
some Precellys beads (Peqlab, Erlangen, Germany) and stored at
70 C until RNA extraction.
2.11. Reverse transcriptase polymerase chain reaction (RT-PCR) and
quantitative real-time PCR (qPCR)
Brain tissues were homogenized with the Precellys 24 homoge-
nizer (Peqlab). RNA extraction was performed according to the
manufacturer’s instructions using the RNeasy lipid tissue mini kit
(Qiagen). The RNA concentration was measured and 2 lg of RNA
was reverse-transcribed in the Mastercycler Gradient (Eppendorf,
Hamburg, Germany), using the high capacity cDNA reverse tran-
scription kit (Life Technologies) according to the manufacturer’s
instructions. A control without reverse transcriptase for each group
and area was always included. For relative quantification of mRNA
levels, qPCR was performed on a LightCycler480 Systemwith Taq-
Man inventoried gene expression assays (listed in Supplementary
Data) and the TaqMan gene expression master mix (Life Technolo-
gies). All samples were measured as triplicates. ACTB, GAPDH and
PPIL3 were used as reference (endogenous housekeeping) genes for
quantification of target gene expression. Quantitative measure-
ments of target gene levels relative to controls were performed
with the 2DDCt method using the mean value of the vehicle-
treated group as the calibrator (Livak and Schmittgen, 2001).
Group differences were expressed as fold changes.
2.12. Colonic content metabolomics
Metabolites in the colonic content of mice were analyzed by
untargeted 1H NMR analysis at the Institute of Biology of Leiden
University (Netherlands). Colonic content extracts were prepared
by mixing 20 mg of frozen luminal colonic content material with
1 mL of saline phosphate buffer that consisted of 1.9 mM Na2HPO4,
8.1 mM NaH2PO4, 150 mM NaCl and 1 mM sodium 3-
(trimethylsilyl)-propionate-D4 (TSP) in D2O. After mixing thor-
oughly, samples were centrifuged at 17,000g for 5 min. Each
supernatant was filtered through a 0.2 lm membrane filter, and
300 lL filtrate was transferred to a 3 mm NMR tube for analysis.High resolution 1H NMR spectra were recorded using a Bruker
AV 600 spectrometer (Bruker, Karlsruhe, Germany). Details of the
spectrometric analysis are given in Supplementary Data.
2.13. Plasma metabolomics
Metabolites in the plasma of mice were analyzed by targeted
LC-HRMS metabolomics according to Bajad et al. (2006) by hydro-
philic interaction liquid chromatography (HILIC) at the HEALTH
Institute for Biomedicine and Health Sciences, JOANNEUM
RESEARCH Forschungsgesellschaft mbH (Graz, Austria). The
plasma samples were processed according to Yuan et al. (2012).
Details of the LC-HRMS procedure are given in Supplementary
Data.
Raw data were converted into mzXML by msConvert (Pro-
teoWizard Toolkit v3.0.5) (Chambers et al., 2012), and metabolites
were targeted-searched by the in-house developed tool PeakScout
(as detailed in Supplementary Data), with a reference list contain-
ing accurate mass and retention times in agreement to standards
outlined by Sumner et al. (2007). Molecular masses for all sub-
stances were taken from the literature and available online data-
bases (HMDB, KEGG, Metlin) (Kanehisa and Goto, 2000; Smith
et al., 2005; Wishart et al., 2007, 2013; Kanehisa et al., 2014). Addi-
tionally, pure substances of all analytes, except lipids, were run on
the same system to obtain reference retention times and fragmen-
tation spectra.
To correct for dilution differences resulting from different blood
volumes (100–560 lL) median normalization was performed. Each
metabolite was scaled 0 to 1 as AUC0-1scaled = (AUC-minimum(AUC))/
(range(AUC)), for each sample the samplemedian was calculated as
the median of all AUC0-1scaled in the sample, and AUC values were
normalized as median normalized AUC = AUC/samplemedian. Finally,
median normalized AUC values were log10 transformed to achieve
sufficiently normal distribution and homoscedasticity in the data
set.
2.14. Antibiotic analysis
A sensitive and selective analytical method for the quantitative
analysis of antibiotics in plasma and brain was developed. Plasma
samples were thawed to room temperature. A 50 lL aliquot was
diluted with 100 lL of 0.1% acetic acid (Sigma-Aldrich), spiked
with 10 ng amoxicillin (Sigma-Aldrich) as internal standard and
mixed. A 30 mg strata-x solid phase extraction cartridge (30 mg;
1 cc; Phenomenex, Aschaffenburg, Germany) was activated (1 mL
methanol (Sigma-Aldrich) followed by 1 mL 0.1% acetic acid), after
which the diluted sample was loaded on the cartridge and washed
with 1 mL of 0.1% acetic acid. Analytes were eluted with 1 mL
methanol. The elution solvent was evaporated to dryness and the
residual sample was resolved in 100 lL of 0.1% formic acid
(Sigma-Aldrich).
For brain analysis, half a brain was placed into 2 mL ZR Bashing
Bead Lysis Tubes (VWR, Vienna, Austria), spiked with 10 ng amox-
icillin (internal standard) and 1 mL water. After homogenization
the vial was centrifuged at 10,000 rpm for 10 min and the super-
natant was used for solid phase extraction. The supernatant was
diluted with 1 mL of 0.1% acetic acid and mixed. A 100 mg
strata-x solid phase extraction cartridge (100 mg, 3 cc; Phenom-
enex) was activated (3 mL methanol followed by 3 mL 0.1% acetic
acid), and the diluted sample was loaded on the cartridge and
washed with 3 mL of 0.1% acetic acid. Analytes were eluted with
3 mL methanol. The elution solvent was evaporated to dryness
and the residual sample was resolved in 200 lL of 0.1% formic acid.
Analysis was performed with an Agilent 6460 triple quadrupole
mass spectrometer equipped with an electrospray ionization
source coupled to a 1290 binary UHPLC system (Agilent, Waldbronn,
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C18 (100  2.1 mm; 2.6 lm) column (Phenomenex) was used.
Gradient elution with a binary mobile phase system of channel
A (0.1% formic acid in water) and channel B (0.1% formic acid in
acetonitrile (Sigma-Aldrich)) was performed at 30 C column tem-
perature and a 0.4 mL/min flow rate. The gradient profile was 3%
channel B for 0.5 min, linearly increased to 24% channel B over
1.5 min and ramped to 90% channel B over 0.1 min. The run time
was set to 3.5 min following a post time of 1.5 min. The autosam-
pler was maintained at 4 C and the injection volume was set at
5 lL. Mass spectrometry detection was conducted in positive
mode, using dynamic multiple reaction monitoring. The cycle time
was set at 250 ms. Two precursor/product ion transitions were
used as quantifier and qualifier for each analyte, respectively.
Quantitation was performed using the ion transitions m/z
366.1?m/z 349;114 (amoxicillin; internal standard), m/z
350.1?m/z 114;106 (ampicillin) and m/z 724.8?m/z 144;100.1
(vancomycin). According to bioanalytical validation guidelines
the method was tested for the following parameters: selectivity,
linearity, lower limit of quantification (LLOQ), accuracy and preci-
sion, extraction efficiency, matrix effect, and autosampler stability.
Calibration curves were constructed using linear regression with
1/x2 weighting based on a minimum of 8 calibrator peak area ratios,
excluding the blank. Calibration levels were 0.1, 0.2, 0.5, 1.0, 2.0, 5.0,
10, 20, 50, 100 and 200 ng/mL for ampicillin and 1.0, 2.0, 5.0, 10, 20,
50, 100 and 200 ng/mL for vancomycin. Calibrators and triplicate
quality control samples at low, medium and high concentrations
were analyzed in each set of specimens. Samples in which no antibi-
otic was detected were labeled with the respective LLOQ value for
numerical evaluation and statistical comparison.
2.15. Statistics
Results were statistically evaluated either with SPSS 22 (SPSS
Inc., Chicago, IL, USA) or with R (R Development Core Team,
2011) (v3.2.1, packages stats, missMDA, nlme) using Tibco Spot-
fire (v7.0.0). Principal component analysis (PCA) was performed
centered and scaled to unit variance (R function prcomp). Missing
values of NMR metabolites were imputed by zero, missing values
of LC-MS metabolites by a regularized expectation-maximization
(function imputePCA and estim_ncpPCA). For all data except LC-
MS metabolomics differences between two independent groups
were analyzed with the independent samples t-test in SPSS. The
homogeneity of variances was assessed with the Levene test. In
case of a non-parametric distribution of data the Mann–WhitneyFig. 2. Brain concentrations of ampicillin and vancomycin are below the respective low
vancomycin (B) in plasma and brain after 10 days of antibiotic (AB) treatment. The bars r
Mann-Whitney U test.U test was used. For repeated measurements repeated measures
analysis of variance (ANOVA) was performed. For multiple compar-
isons, p-values were adjusted with the false discovery rate. Proba-
bility values of p 6 0.05 were regarded as statistically significant.
Pearson’s correlation coefficient was used to determine correla-
tions between variables.
For microbiome analysis the ADONIS test of weighted UniFrac
distances was conducted with the QIIME compare_categories
script. For LC-MS metabolomics the normal data distribution was
found to be sufficient according to Shapiro-Wilk (91% normally dis-
tributed) and Kolmogorov-Smirnov (99% normally distributed)
after log10 transformation of median normalized AUC. Scedasticity
was found to be sufficient according to Bartlett (86% homoscedas-
tic) and Levene (81% homoscedastic) after log10 transformation of
median normalized AUC. Differences between two independent
groups were analyzed by a simple ANOVA (R function aov) model
with the categorically fixed factor treatment. p-Values were
adjusted according to Benjamini-Hochberg (R function p.adjust).
3. Results
3.1. Brain levels of ampicillin and vancomycin are below the lower
limit of quantification at the time point of cognitive testing
Multiple antibiotics with little or no oral bioavailability were
used to ablate a wide range of bacteria specifically in the intestine.
Of the antibiotics chosen (ampicillin, bacitracin, meropenem, neo-
mycin, vancomycin), only ampicillin is absorbed to some extent
from the human gut (Craig and Stitzel, 2004; Lafforgue et al.,
2008). In order to examine whether ampicillin enters murine circu-
lation and brain, plasma and brain levels of ampicillin were com-
pared with those of vancomycin, a non-absorbable antibiotic, at a
time point when cognitive performance was assessed (day 10).
The plasma levels of ampicillin were around 2 ng/mL in
antibiotic-treated mice (Fig. 2A) while the plasma concentrations
of vancomycin were, except for two samples, below the LLOQ of
1 ng/mL (Fig. 2B). In the brain the concentrations of both ampicillin
(Fig. 2A) and vancomycin (Fig. 2B) were below the respective LLOQ.
3.2. Antibiotic treatment strongly disrupts microbial composition in
the colon
Antibiotic treatment vigorously changed the microbiome,
reducing bacterial load (Fig. 3A) and diversity of bacteria
(Fig. 3B). Principal coordinate analysis (PCoA) showed thater limit of quantification. The graphs depict concentrations of ampicillin (A) and
epresent means + SEM, n = 6–8; **p 6 0.01 compared to vehicle (VEH)-treated mice,
Fig. 3. Antibiotic treatment strongly disrupts and diminishes the microbial community in the colon. Mice were treated with antibiotic (AB) mix or vehicle (VEH) by gavage for
11 days. (A) Principal coordinate analysis (PCoA) plot based on weighted UniFrac distance between samples. The microbiome analysis blank is depicted as a dot highlighted
by an arrow. Two individual dots of antibiotic-treated mice are not visible because they are overlaid by other dots. (B) Alpha-rarefaction curves using the chao1 index. Values
in B represent medians ± SD, n = 10–12.
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ADONIS test) microbial community than vehicle-treated mice
(Fig. 3A). The profile of the microbial composition of antibiotic-
treated mice clustered more closely to the blank than to the profile
of vehicle-treated mice, indicating that most of the commensal
bacteria were eradicated by antibiotic treatment (Fig. 3A). The
residual operational taxonomic units (OTU) in antibiotic-treated
mice represent mainly bacterial species known to be common con-
taminations of DNA extraction and PCR reagents and solutions
(Salter et al., 2014) (see Supplementary Table 1).
3.3. Antibiotic treatment strongly decreases microbial metabolite
levels in the colonic luminal contents
Given that the gut microbiota contributes to digestion (Russell
et al., 2013), antibiotic-induced changes in the microbial commu-nity profile are likely to alter the colonic metabolite profiles. Untar-
geted 1H NMR analysis revealed a separation of the treatment
groups, which indicates a considerable difference in colonic meta-
bolic composition (Fig. 4A and B). Many metabolites known to be
produced by the colonic microbiota were decreased in the luminal
contents of antibiotic-treated mice. In particular, the levels of the
short-chain fatty acids (SCFA) acetate, butyrate and propionate as
well as of trimethylamine, adenine and uracil were significantly
diminished by antibiotic treatment (Fig. 4C).3.4. Antibiotic treatment alters the profile of circulating metabolites,
but not cytokines
As microbial colonization impacts on circulating metabolites
(Wikoff et al., 2009), the plasma metabolic profile was assessed
Fig. 4. Distinct microbial metabolite levels in the colonic contents are markedly decreased by antibiotic treatment. Mice were treated with antibiotic (AB) mix or vehicle
(VEH) by gavage for 11 days. (A) Scores plot of the principal component analysis (PCA) with 21 identified colonic metabolites analyzed by 1H NMR, showing group separation
in the first and fourth components. (B) Corresponding loadings plot, showing the contribution of metabolites to group separation. The metabolites are colored according to p-
values calculated with the Mann-Whitney U test. (C) Graphs of significantly different metabolites. Vertical bars represent the group mean, whiskers SD, n = 10–12; **p 6 0.01,
***p 6 0.001 compared to VEH-treated mice, Mann-Whitney U test.
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lites, 148 were suitable for multivariate and univariate statistical
analyses. PCA showed that the treatment groups separated to a sig-
nificant extent, indicating a marked difference in overall plasma
metabolic composition (Fig. 5A and B). In particular, 11 metaboliteswere present in significantly different amounts in antibiotic-
treated mice compared to vehicle-treated animals (Fig. 5B). The
levels of corticosterone, sphingomyelin 34:1, phosphatidylinositol
38:5, phosphatidylcholine (PC) 36:2, PC 38:5, PC 40:5 and PC
40:8 were significantly increased in antibiotic-treated mice
Fig. 5. Circulating metabolite levels are markedly altered by antibiotic treatment. Mice were treated with antibiotic (AB) mix or vehicle (VEH) by gavage for 11 days. (A)
Scores plot of the principal component analysis (PCA) with 148 identified circulating metabolites analyzed by LC-MS, showing group separation in the second and third
components. (B) Corresponding loadings plot, showing the contribution of metabolites to group separation. Metabolites are colored according to Benjamini-Hochberg
adjusted p-values. (C) Graphs of selected metabolites that were significantly different. Corticosterone and trimethylamine-N-oxide are not shown in the loadings plot because
they were only suitable for univariate analysis. Levels of deoxycholic acid/chenodeoxycholic acid were below the limit of detection in AB-treated mice. Vertical bars represent
the group mean, whiskers SD, n = 8–10; *p 6 0.05, **p 6 0.01, ***p 6 0.001 compared to VEH-treated mice, Benjamini-Hochberg adjusted p-values. AUC, area under the curve;
PC, phosphatidylcholine; PI, phosphatidylinositol; LPC, lysophosphatidylcholine; SM, sphingomyelin.
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cresyl sulfate were reduced (Fig. 5C). The relative levels of corticos-
terone measured by metabolomic analysis corresponded well with
those measured immunochemically (see Supplementary Fig. 1).Moreover, the antibiotic-induced reduction of circulating
trimethylamine-N-oxide levels (Fig. 5C) concorded with the reduc-
tion of this metabolite in the colonic contents (Fig. 4C). The levels
of deoxycholic acid/chenodeoxycholic acid were below the limit of
Fig. 6. Object recognition memory is impaired in antibiotic-treated mice whereas spatial learning and memory remain intact. Mice were treated with antibiotic (AB) mix or
vehicle (VEH) by gavage for 11 days. In the NORT (A) a positive memory index (MI) indicates that the mice spent more time exploring the novel object than the known object.
In the BM test (B and C) panel B shows the decrease in target latency with consecutive training trials, and panel C shows memorization of the target hole in the target
quadrant on the probe day. Values represent means + SEM, n = 6–8 (A), n = 7–8 (B), n = 6–7 (C); *p 6 0.05 compared to VEH-treated mice, t-test.
Fig. 7. Antibiotic treatment alters tight junction protein mRNA expression in amygdala and hippocampus. Mice were treated with antibiotic (AB) mix or vehicle (VEH) by
gavage for 11 days. The panels show the expression of tight junction protein 1 (TJP1), claudin 5 (CLDN5) and occludin (OCLN) mRNA in the medial prefrontal cortex (A),
hippocampus (B), amygdala (C), and hypothalamus (D). mRNA expression is expressed as fold change relative to VEH-treated mice. Values represent means + SEM, n = 10–12;
*p 6 0.05, **p 6 0.01, ***p 6 0.001 compared to VEH-treated mice, t-test.
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mice the metabolite was clearly present (Fig. 5C).
The plasma concentrations of interleukin (IL)-1b, IL-6, IL-10,
tumor necrosis factor (TNF)-a and interferon (IFN)-c did not differ
between vehicle- and antibiotic-treated mice (see Supplementary
Fig. 1).3.5. Novel object recognition memory is impaired in antibiotic-treated
mice whereas spatial learning and memory remains intact
Since memory is impaired in GF mice (Gareau et al., 2011), we
evaluated non-spatial memory with the NORT on day 10 of the
antibiotic treatment and, in a separate group of animals, spatial
Fig. 8. Antibiotic treatment alters the expression of neural signaling-related molecules in a brain region-specific manner. Mice were treated with antibiotic (AB) mix or
vehicle (VEH) by gavage for 11 days. The panels show the expression of brain-derived neurotrophic factor (BDNF), N-methyl-D-aspartate receptor subunit 2B (GRIN2B) and
serotonin transporter (SLC6A4) mRNA in the medial prefrontal cortex (A), hippocampus (B), amygdala (C), and hypothalamus (D). mRNA expression is expressed as fold
change relative to VEH-treated mice. Values represent means + SEM, n = 10–12; *p 6 0.05, **p 6 0.01, ***p 6 0.001 compared to VEH-treated mice, t-test.
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otic treatment (Fig. 6A–C). Antibiotic-treated mice had a signifi-
cantly lower memory index than vehicle-treated mice (Fig. 6A),
which indicates a disruption of novel object recognition memory.
The BM test revealed that spatial learning (Fig. 6B) and memory
(Fig. 6C) were not changed by the antibiotic treatment. Repeated
measures ANOVA revealed that only the number of trials signifi-
cantly influenced target latency (F(4, 52) = 7.561; p 6 0.001).
3.6. Antibiotic treatment differentially alters tight junction protein and
cytokine mRNA expression in the amygdala and hippocampus
As tight junction protein expression in frontal cortex, striatum
and hippocampus is lowered in GF mice (Braniste et al., 2014),
we measured mRNA expression of three tight junction proteins
in four brain regions of antibiotic-treated mice (Fig. 7A–D). Brain
regions were chosen based on their importance in cognition and
memory (amygdala, medial prefrontal cortex, hippocampus), and
the established impact of the gut microbiota on the
hypothalamic-pituitary-adrenal (HPA) axis (hypothalamus) (Sudo
et al., 2004). In the medial prefrontal cortex (Fig. 7A) and hypotha-
lamus (Fig. 7D) the expression of the tight junction proteins clau-
din 5 (CLDN5), tight junction protein 1 (TJP1) and occludin
(OCLN) was similar in vehicle- and antibiotic-treated animals. In
the hippocampus, however, antibiotic treatment significantly
reduced the expression of CLDN5 and OCLN mRNA (Fig. 7B). Theexpression of TJP1 and OCLN mRNA in the amygdala was increased
in antibiotic-treated mice relative to vehicle controls (Fig. 7C).
Antibiotic treatment failed to enhance the expression of
IL-1b, IL-6, TNF-a, IFN-c and chemokine (C-C motif) ligand 2
(CCL2) mRNA in any of the four brain regions examined (see
Supplementary Fig. 2).3.7. Antibiotic treatment alters expression patterns of neural signaling-
related molecules in the brain
Given that cognitive performance is impaired in antibiotic-
treated mice, we examined the cerebral expression of neural
signaling-related molecules that are related to learning and mem-
ory. Particular focus was put on brain-derived neurotrophic factor
(BDNF), N-methyl-D-aspartate receptor subunit GRIN2B (glutamate
receptor, ionotropic, NMDA2B, epsilon 2) and serotonin transporter
SLC6A4 (solute carrier family 6, neurotransmitter transporter,
member 4), all of which may be involved in the cognitive deficit
of GF mice (Sudo et al., 2004; Neufeld et al., 2011; Gareau et al.,
2011; Clarke et al., 2013). In the medial prefrontal cortex
(Fig. 8A), hippocampus (Fig. 8B) and hypothalamus (Fig. 8D) BDNF
mRNA expression was significantly diminished in antibiotic-
treated mice. In contrast, the expression of GRIN2B and SLC6A4
was left unaltered by antibiotic treatment in these three brain
regions. In the amygdala, however, the expression of GRIN2B and
Fig. 9. Antibiotic treatment alters the expression of neuropeptide Y and its receptors in a region-specific manner. Mice were treated with antibiotic (AB) mix or vehicle (VEH)
by gavage for 11 days. The panels show the expression of neuropeptide Y (NPY) and the NPY receptors NPY1R, NPY2R and NPY5R in the medial prefrontal cortex (A),
hippocampus (B), amygdala (C), and hypothalamus (D). mRNA expression is expressed as fold change relative to VEH-treated mice. Values represent means + SEM, n = 10–12;
*p 6 0.05, **p 6 0.01, ***p 6 0.001 compared to VEH-treated mice, t-test.
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mRNA was not affected (Fig. 8C).
Since NPY is involved in the regulation of cognitive processes
(Lach and de Lima, 2013; Reichmann and Holzer, 2015; Tasan
et al., 2015) and its mRNA expression is increased in GF mice
(Schele et al., 2013), we examined the expression of NPY and three
of its receptors (Y1, NPY1R; Y2, NPY2R; Y5, NPY5R) in four brain
regions of antibiotic-treated mice (Fig. 9A–D). In the medial pre-
frontal cortex no differences in the expression of NPY, NPY1R,
NPY2R and NPY5R mRNA between vehicle- and antibiotic-treated
mice were found (Fig. 9A). Antibiotic treatment led to a significant
attenuation of NPY1R and NPY2R mRNA expression in the hip-
pocampus (Fig. 9B), but NPY and NPY5R expression remained unal-
tered. Conversely, in the amygdala of antibiotic-treated mice NPY
mRNA expression was significantly elevated and NPY5R expression
decreased whereas NPY1R and NPY2R mRNA expression stayed
unchanged (Fig. 9C). In the hypothalamus antibiotic treatment
led to a prominent increase in NPY mRNA expression but did not
affect the expression of any NPY receptor under study (Fig. 9D).4. Discussion
The present study shows that intragastric treatment of mice
with an antibiotic mix impairs novel object recognition, but not
spatial memory. This behavioral change is associated with a dis-
ruption of the microbial community in the colon, distinct alter-
ations of the colonic and circulating metabolite profile andparticular changes of neurochemical brain activity. Although ampi-
cillin was absorbed to some extent into the circulation, it remained
undetectable in the brain. Neurotoxic effects may only occur if very
high doses of ampicillin are given parenterally, the blood-brain
barrier is leaky, and ampicillin’s concentration in the cerebrospinal
fluid is elevated (Browning and Tune, 1983; Grill and Maganti,
2011). We therefore conclude that it is gut dysbiosis rather than
a systemic antibiotic response that causes cognitive impairment.
Furthermore, we propose that short-term treatment with antibi-
otics, which do not reach the brain, is a valid model to probe
causality in microbiota-dependent changes of brain function and
behavior. In substantiating this conclusion we address the multiple
actions of antibiotic treatment along the gut microbiota-brain axis
and compare them with the relevant phenotype of GF mice.4.1. Intragastrically administered non-absorbable antibiotics are
unlikely to reach the brain
Intragastric treatment of mice with non-absorbable antibi-
otics was used to specifically deplete the gut of a wide range
of bacteria, including gram-positive as well as gram-negative
anaerobic taxa. Of the antibiotics employed here (ampicillin,
bacitracin, meropenem, neomycin, vancomycin), only ampicillin
is known to have some oral bioavailability in humans (Craig
and Stitzel, 2004; Lafforgue et al., 2008). Since a limited amount
of ampicillin was found in murine plasma, but not brain tissue,
following gastric gavage we conclude that the antibiotics under
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behavioral and neurochemical analysis. Although systemic
actions of circulating ampicillin cannot be excluded, intact spa-
tial memory and a lack of cytokine upregulation (see Supple-
mentary Fig. 2) negate a direct effect on the brain. In keeping
with this contention, global vitality markers such as body
weight, feeding and drinking (see Supplementary Fig. 3) like-
wise stayed unchanged. In addition, histology of the small and
large intestine failed to unveil any signs of inflammation (see
Supplementary Fig. 4).
4.2. Multiple antibiotic treatment causes dysbiosis and metabolite
depletion in the gut
Antibiotic treatment profoundly disturbed the colonic microbial
community and gut dysbiosis manifested itself in changes of sev-
eral metabolite concentrations in the colonic luminal contents.
The depletion of the SCFAs acetate, n-butyrate and propionate,
which are products of microbial fermentation of dietary fiber, is
in agreement with other studies (Yap et al., 2008; Romick-
Rosendale et al., 2009; Swann et al., 2011a). Dietary choline is
either metabolized to glycine by a mammalian pathway or pro-
cessed to trimethylamine by gut bacterial enzymes (Zeisel et al.,
1985). The depletion of trimethylamine in our study might indicate
that choline metabolism was shifted towards the glycine pathway.
Reduced bacterial load may also be the cause for the fall of colonic
adenine and uracil contents in antibiotic-treated mice, since the
colonic levels of nucleobases (adenine, cytosine, guanine and ura-
cil) are likewise reduced in GF mice (Matsumoto et al., 2012). It
should be noted, however, that the biochemical effects of antibiotic
treatment in the colon were largely restricted to bacteria-derived
metabolites (see Supplementary Table 2).
4.3. Circulating metabolites may be messengers in the communication
between gut dysbiosis and brain
In contrast to circulating cytokines which remained unaltered
(see Supplementary Fig. 1), the levels of several plasma metabo-
lites (lipid species and converted bacteria-derived molecules) were
significantly altered in antibiotic-treated mice. These changes are
not fully congruent with those seen in GF mice (Wikoff et al.,
2009; Velagapudi et al., 2010; Swann et al., 2011b). Whereas many
PCs and sphingomyelins are decreased in the serum of fasted GF
mice, PC 36:2 is increased in serum and adipose tissue
(Velagapudi et al., 2010). While this is in agreement with the pre-
sent findings in antibiotic-treated mice, the serum levels of PC
40:5, PC 40:8 and sphingomyelin 34:1 were increased in
antibiotic-treated mice but left unaltered in fasted GF mice
(Velagapudi et al., 2010). Given that the metabolism of PC and
LPC is interconnected (Richmond and Smith, 2011), the increase
in PC and concomitant decrease in LPC levels in antibiotic-
treated mice points to a decrease in PC lipolysis. Unlike the LPC
levels, the plasma concentration of phosphatidylinositol 38:5 was
elevated in antibiotic-treated mice. As PCs are relevant to biologi-
cal membrane structure and membrane-mediated cell signaling
(Exton, 1990), a change in their circulating concentrations may
have an impact on many organs including the brain. It remains
to be elucidated in which way the gut microbiota modifies dietary
absorption and hepatic biosynthesis of these important lipid spe-
cies (Velagapudi et al., 2010).
The circulating levels of p-cresyl sulfate were markedly
decreased in antibiotic-treated mice, which is in line with the
absence of p-cresol sulfate in the serum of GF mice (Wikoff et al.,
2009). Given that bacterial fermentation of dietary tyrosine gener-
ates p-cresol sulfate which is then absorbed and further metabo-
lized to p-cresyl sulfate by the host (Meijers and Evenepoel,2011), decreased levels of p-cresyl sulfate reflect a lack of gut bac-
terial enzymes. A similar explanation applies to the decrease in the
plasma levels of trimethylamine-N-oxide, an oxidation product of
trimethylamine (Rebouche and Chenard, 1991). The unconjugated
secondary bile acid deoxycholic acid, which is produced by intesti-
nal bacteria (Ridlon et al., 2006) and which could not be differen-
tiated from the primary bile acid chenodeoxycholic acid due to
isomerism, was completely depleted from the plasma of
antibiotic-treated mice. As the levels of unconjugated bile acids
are also decreased in plasma, heart, liver and kidney tissue of GF
mice (Swann et al., 2011b), it is obvious that disruption of the
gut microbial community has a strong impact on bile acid metabo-
lism (Ridlon et al., 2006). The observation that nucleobase concen-
trations were not changed in the plasma of antibiotic-treated mice
(see Supplementary Table 3) may indicate that the nucleobase
depletion in the colonic contents reflects reduced bacterial load
rather than changes in endogenous production.
Taken all metabolite data together, it is evident that gut
dysbiosis-related changes in the concentrations of several circulat-
ing molecules may be a means to signal to the brain and modify its
function. Cytokines are unlikely to be involved in this communica-
tion as deduced from the present study. These data add to the
important search for specialized metabolites whereby the gut
microbiota impacts on the brain in health and disease (Sharon
et al., 2014).4.4. Antibiotic-induced dysbiosis impairs cognitive performance
GF mice exhibit a deficit in non-spatial and working memory as
assessed with the NORT and T-maze, respectively (Gareau et al.,
2011). The current findings thus add to the emerging concept that
factors emanating from the gut microbiota impact on cognitive
performance (Gareau et al., 2011; Neufeld et al., 2011; Farzi
et al., 2012; Davari et al., 2013; Gareau, 2014; Desbonnet et al.,
2015).
The specific disturbance of this type of learning and memory
also supports the conclusion that antibiotic-induced dysbiosis as
studied under the current experimental conditions does not have
a generalized, or neurotoxic, effect on brain function. The finding
that in none of the cerebral areal areas under study (medial pre-
frontal cortex, hippocampus, amygdala, hypothalamus) the expres-
sion of cytokines was enhanced (see Supplementary Fig. 2) affirms
this contention and indicates that neuroinflammatory processes
were not induced by gut dysbiosis.4.5. Cognitive impairment due to gut dysbiosis is associated with
changes in the expression of tight junction proteins, brain-derived
neurotrophic factor, N-methyl-D-aspartate receptor subunit 2B,
serotonin transporter, NPY system and corticosterone
In analyzing neurochemical alterations that may underlie the
cognitive deficit evoked by gut dysbiosis we focused on the medial
prefrontal cortex, hippocampus and amygdala, all of which make
distinct contributions to object recognition (Moses et al., 2005;
Balderas et al., 2008; Broadbent et al., 2009; Barker and
Warburton, 2011; Antunes and Biala, 2012; Beldjoud et al.,
2015). In addition, the hypothalamus was included in view of the
established impact of the gut microbiota on HPA axis activity
(Sudo et al., 2004) and the role of corticosteroids in cognitive func-
tion (McEwen, 2007). The molecular analysis focused on mRNA
quantitation, because this parameter provides a better reflection
of the dynamics of intervention-induced gene expression in neu-
ronal somata than peptide or protein levels that may mirror home-
ostatic balance between translation, storage capacity, axonal
transport and neuronal release (Larsen et al., 1993; Ji et al., 1994).
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rier is regulated by the gut microbiota (Braniste et al., 2014), and a
decrease in tight junction protein expression is thought to reflect
an increase in blood-brain barrier permeability (Tietz and
Engelhardt, 2015). Antibiotic-induced gut dysbiosis was associated
with a downregulation of OCLN and CLDN5 in the hippocampus, as
also seen in GF mice (Braniste et al., 2014), whereas OCLN and TJP1
were upregulated in the amygdala. Although the underlying mech-
anisms are not yet understood, our data add to the contention that
the gut microbiota has an influence on the blood-brain barrier, the
functionality of which modulates information transfer between the
gut and brain. The change in cerebral tight junction expression in
antibiotic-treated mice did not, however, translate into neuroin-
flammatory processes as would be reflected by increased cytokine
expression in the brain.
There is ample evidence that BDNF plays a role in synaptic plas-
ticity and cognition (Rattiner et al., 2005; Lu et al., 2014), and BDNF
expression has been found to be altered both in GF mice (Sudo
et al., 2004; Diaz Heijtz et al., 2011; Clarke et al., 2013; Schele
et al., 2013) and mice with antibiotic-induced gut dysbiosis
(Bercik et al., 2011; Desbonnet et al., 2015). We found a positive
correlation between hippocampal BDNF expression and the mem-
ory index of the NORT in antibiotic-treated mice (Pearson’s corre-
lation; r = 0.775, p = 0.024), which attests to a strong relationship
between the deficit of hippocampal BDNF and the disturbance of
novel object recognition memory.
Enhanced forebrain expression of GRIN2B, which encodes one
subunit of the N-methyl D-aspartate glutamate receptor, is associ-
ated with improved performance in the NORT (Tang et al., 1999;
Niimi et al., 2008). In the present study the expression of GRIN2B
remained unaltered in the medial prefrontal cortex, but increased
in the amygdala, which is at variance with the decreased formation
of GRIN2B in the central amygdala of GF mice (Neufeld et al., 2011).
In view of the established role of the amygdala in the regulation of
anxiety it remains to be explored whether this disparity is of rele-
vance to the observation that anxiety-like behavior is attenuated in
GF mice but left unaltered in the antibiotic-treated mice of the cur-
rent study (see Supplementary Fig. 5).
There is ample evidence that the metabolism and activity of
tryptophan-derived mediators such as serotonin and kynurenine
are under the influence of the gut microbiota (Diaz Heijtz et al.,
2011; Desbonnet et al., 2015; O’Mahony et al., 2015; Yano
et al., 2015). Serotonin-mediated neurotransmission is regulated
by reuptake of this indoleamine into the presynaptic nerve termi-
nals via a serotonin transporter encoded by the gene SLC6A4.
Inhibition of serotonin reuptake by fluoxetine has been found
to improve novel object recognition memory in stressed mice
(El Hage et al., 2004; Urani et al., 2011) but to impair it in
non-stressed mice (Carlini et al., 2012). A potential implication
of serotonin reuptake in gut dysbiosis-mediated alterations in
brain function can be deduced from the enhanced expression of
SLC6A4 specifically in the amygdala of antibiotic-treated mice.
There was a negative correlation between SLC6A4 expression in
the amygdala and the NORT memory index (Pearson’s correla-
tion; r = 0.711, p = 0.048) as well as a negative correlation
between BDNF expression in the hippocampus and SLC6A4
expression in the amygdala (Pearson’s correlation; r = 0.679,
p = 0.015). These relationships suggest that the serotonin system
in the amygdala is in some way involved in the object recognition
deficit of antibiotic-treated mice.
Another messenger with a potential implication in the cognitive
impairment due to gut dysbiosis is NPY, given that this peptide is
involved in various physiologic functions including cognition
(Farzi et al., 2015; Reichmann and Holzer, 2015). NPY expression
was markedly enhanced in the amygdala and hypothalamus of
antibiotic-treated mice, a change that has also been reported forGF mice (Schele et al., 2013). Since antibiotic treatment did not
increase food intake (see Supplementary Fig. 3), we hypothesize
that elevated NPY expression in the hypothalamus and amygdala
is related to the elevated plasma level of corticosterone (Lee
et al., 2009; Gelfo et al., 2012; Farzi et al., 2015). Increased NPY
synthesis in the amygdala and hypothalamus may also be the rea-
son why anxiety- and depression-like behavior remained
unchanged despite a rise in plasma corticosterone (see Supplemen-
tary Fig. 1 and Fig. 5), which otherwise is known to enhance
anxiety- and depression-like behavior (Lee et al., 2009;
Kutiyanawalla et al., 2011; Baldock et al., 2014; Farzi et al.,
2015). In addition, increased hypothalamic NPY formation may
have contributed to the decreased BDNF expression in the
hypothalamus (Gelfo et al., 2012).
The antibiotic-induced upregulation of NPY in the amygdala
and hypothalamus was matched by a downregulation of NPY1R
and NPY2R in the hippocampus. In line with their preferential
post- and presynaptic location, respectively, NPY1R and NPY2R
often mediate opposing effects of NPY in neurotransmission and
behavior (Farzi et al., 2015). While NPY1R plays an important role
in maintaining stress resilience and emotional-affective homeosta-
sis, NPY2R has also been implicated in cognition and schizophrenia
(Farzi et al., 2015). It is particularly worth noting that NPY2R
knockout mice exhibit a similar deficit in novel object recognition
memory (Redrobe et al., 2004; Painsipp et al., 2008) as the
antibiotic-treated mice in the current study. Decreased NPY2R
expression in the hippocampus could hence be a crucial factor in
the cognitive impairment due to gut dysbiosis. The antibiotic-
induced increase of NPY expression in the amygdala occurred
alongside a decrease in NPY5R expression. The functional rele-
vance of this finding in the context of the current study remains
to be analyzed as the implication of NPY5R in cognition is still little
understood (Farzi et al., 2015).
The plasma concentration of corticosterone was enhanced in
antibiotic-treated mice, which is reminiscent of the exaggerated
corticosterone response of GF mice to stress (Sudo et al., 2004).
Enhanced circulating corticosterone could have a bearing on the
cognitive deficit seen in antibiotic-treated mice, since chronic
stress-induced enhancement of glucocorticoid levels has a nega-
tive impact on cognitive function (McEwen, 2007). In addition,
the rise of plasma corticosterone in antibiotic-treated mice
may, in analogy to other findings (Dwivedi et al., 2006; Naert
et al., 2015), contribute to the downregulation of BDNF seen in
the hypothalamus.4.6. Conclusions
Taking all data together, we show that a short-term intragastric
treatment of adult mice with an antibiotic mixture disrupts the
bacterial community in the colon, specifically impairs novel object
recognition memory and causes distinct alterations in circulating
metabolite levels and in the expression of molecules relevant to
cerebral function. Profound alterations in the metabolite profile
of the colon and circulation may be relevant to the communication
between gut and brain. The cognitive impairment due to gut dys-
biosis is related to changes in the expression of tight junction pro-
teins, BDNF, GRIN2B, the serotonin transporter, the NPY system
and HPA axis activity. Several of the behavioral and biochemical
alterations brought about by short-term antibiotic treatment are
similar to those found in GF mice although distinct differences
have also been noted. Our findings add to the understanding of
the microbiota-gut-brain axis and highlight the potential and lim-
itation of antibiotic-induced gut dysbiosis as model system to
probe causality in the interaction between gut microbiota and
brain.
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